Form 4: Neurocrine Biosciences Executive Ingrid Delaet Reports Stock Transactions

Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, reports the acquisition and disposition of company stock and derivative securities under a pre-arranged trading plan.

Summary

• On March 8, 2024, Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, acquired 1,800 shares of common stock through the exercise of non-qualified stock options at a price of $106.02 per share.
• On the same day, Delaet disposed of 1,800 shares of common stock at a weighted average price of $140.0292 per share.
• On March 11, 2024, Delaet acquired 200 shares of common stock through the exercise of non-qualified stock options at a price of $106.02 per share.
• Also on March 11, 2024, Delaet disposed of 200 shares of common stock at a price of $140 per share.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on November 29, 2023.
• Following these transactions, Delaet beneficially owns 7,507 shares of common stock and 7,367 non-qualified stock options.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating a planned and potentially non-discretionary approach to stock sales.

Industry Context

Form 4 filings are a routine part of insider trading activity and provide transparency into the transactions of company executives. The use of a 10b5-1 trading plan is a common practice to avoid accusations of insider trading.

Comparison to Industry Standards

• Executive stock transactions are common across publicly traded companies, and the reporting requirements are standardized by the SEC.
• The use of 10b5-1 trading plans is a widespread practice among executives to manage their stock holdings while complying with insider trading regulations.
• Comparable companies in the biotechnology sector, such as Amgen (AMGN) and Gilead Sciences (GILD), also see regular Form 4 filings from their executives.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, as they provide insight into executive stock ownership.
• The use of a 10b5-1 trading plan suggests a long-term perspective and adherence to regulatory guidelines.

Key Dates